REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

2026-03-03 - 15:37

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ — REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL now offers